Clinical‐grade validation of whole genome sequencing reveals robust detection of low‐frequency variants and copy number alterations in CLL

The 100 000 Genome Project aims to develop a diagnostics platform by introducing whole genome sequencing (WGS) into clinical practice. Samples from patients with chronic lymphocytic leukaemia were subjected to WGS. WGS detection of single nucleotide variants and insertion/deletions were validated by targeted next generation sequencing showing high concordance (96·3%), also for detection of sub‐clonal variants and low‐frequency TP53 variants. Copy number alteration detection was verified by fluorescent in situ hybridisation and genome‐wide single nucleotide polymorphism array (concordances of 86·7% and 92·9%, respectively), confirming adequate sensitivity by WGS. Our results confirm that WGS can provide comprehensive genomic characterisation for clinical trials, drug discovery and, ultimately, precision medicine.

[1]  T. Shanafelt,et al.  Chronic lymphocytic leukaemia , 2018, The Lancet.

[2]  Daniele Merico,et al.  Improved diagnostic yield compared with targeted gene sequencing panels suggests a role for whole-genome sequencing as a first-tier genetic test , 2017, Genetics in Medicine.

[3]  S. Lade,et al.  Clinicopathological features and outcomes of progression of CLL on the BCL2 inhibitor venetoclax. , 2017, Blood.

[4]  K. Stamatopoulos,et al.  Immunoglobulin gene sequence analysis in chronic lymphocytic leukemia: updated ERIC recommendations , 2017, Leukemia.

[5]  J. Gribben,et al.  Results of the randomized phase IIB ADMIRE trial of FCR with or without mitoxantrone in previously untreated CLL , 2017, Leukemia.

[6]  A. Schuh,et al.  Results of the randomized phase IIB ARCTIC trial of low-dose rituximab in previously untreated CLL , 2017, Leukemia.

[7]  Carme Camps,et al.  Clinical applicability and cost of a 46-gene panel for genomic analysis of solid tumours: Retrospective validation and prospective audit in the UK National Health Service , 2017, PLoS medicine.

[8]  N. Popitsch,et al.  Identifying High-Risk CLL to Predict Early Relapse after FCR Based Treatment Using Whole Genome Sequencing: First Results from the Genomics England CLL Pilot , 2016 .

[9]  G. Getz,et al.  Survival of Del17p CLL Depends on Genomic Complexity and Somatic Mutation , 2016, Clinical Cancer Research.

[10]  Xiaoyu Chen,et al.  Manta: rapid detection of structural variants and indels for germline and cancer sequencing applications , 2016, Bioinform..

[11]  E. Montserrat,et al.  Innovation in the prognostication of chronic lymphocytic leukemia: how far beyond TP53 gene analysis can we go? , 2016, Haematologica.

[12]  Steve Lee,et al.  Canvas: versatile and scalable detection of copy number variants , 2016, bioRxiv.

[13]  Michael C. Heinold,et al.  A comprehensive assessment of somatic mutation detection in cancer using whole-genome sequencing , 2015, Nature Communications.

[14]  A. Pettitt,et al.  Presence of multiple recurrent mutations confers poor trial outcome of relapsed/refractory CLL. , 2015, Blood.

[15]  Gabor T. Marth,et al.  A global reference for human genetic variation , 2015, Nature.

[16]  A. Valencia,et al.  Non-coding recurrent mutations in chronic lymphocytic leukaemia , 2015, Nature.

[17]  T. Zander,et al.  Implementation of Amplicon Parallel Sequencing Leads to Improvement of Diagnosis and Therapy of Lung Cancer Patients , 2015, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

[18]  Davis J. McCarthy,et al.  Factors influencing success of clinical genome sequencing across a broad spectrum of disorders , 2015, Nature Genetics.

[19]  G. McVean,et al.  Integrating mapping-, assembly- and haplotype-based approaches for calling variants in clinical sequencing applications , 2014, Nature Genetics.

[20]  Alex M. Fichtenholtz,et al.  Development and validation of a clinical cancer genomic profiling test based on massively parallel DNA sequencing , 2013, Nature Biotechnology.

[21]  Semyon Kruglyak,et al.  Isaac: ultra-fast whole-genome secondary analysis on Illumina sequencing platforms , 2013, Bioinform..

[22]  Heidi L. Rehm,et al.  Disease-targeted sequencing: a cornerstone in the clinic , 2013, Nature Reviews Genetics.

[23]  A. McKenna,et al.  Evolution and Impact of Subclonal Mutations in Chronic Lymphocytic Leukemia , 2012, Cell.

[24]  Jenny Taylor,et al.  Monitoring chronic lymphocytic leukemia progression by whole genome sequencing reveals heterogeneous clonal evolution patterns. , 2012, Blood.

[25]  Tom R. Gaunt,et al.  Predicting the Functional, Molecular, and Phenotypic Consequences of Amino Acid Substitutions using Hidden Markov Models , 2012, Human mutation.

[26]  Wendy S. W. Wong,et al.  Strelka: accurate somatic small-variant calling from sequenced tumor-normal sample pairs , 2012, Bioinform..

[27]  Helga Thorvaldsdóttir,et al.  Integrative Genomics Viewer (IGV): high-performance genomics data visualization and exploration , 2012, Briefings Bioinform..

[28]  J. Gribben,et al.  ERIC recommendations on TP53 mutation analysis in chronic lymphocytic leukemia , 2012, Leukemia.

[29]  C. Yau,et al.  Quantification of subclonal distributions of recurrent genomic aberrations in paired pre-treatment and relapse samples from patients with B-cell chronic lymphocytic leukemia , 2012, Leukemia.

[30]  M. Kaminski,et al.  Acquired genomic copy number aberrations and survival in chronic lymphocytic leukemia. , 2011, Blood.

[31]  Martin Goodson,et al.  Stampy: a statistical algorithm for sensitive and fast mapping of Illumina sequence reads. , 2011, Genome research.

[32]  Helga Thorvaldsdóttir,et al.  Integrative Genomics Viewer , 2011, Nature Biotechnology.

[33]  H. Döhner,et al.  TP53 mutation and survival in chronic lymphocytic leukemia. , 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[34]  S A Forbes,et al.  The Catalogue of Somatic Mutations in Cancer (COSMIC) , 2008, Current protocols in human genetics.

[35]  A Benner,et al.  Genomic aberrations and survival in chronic lymphocytic leukemia. , 2000, The New England journal of medicine.

[36]  E. Montserrat,et al.  appendix 6: Chronic lymphocytic leukaemia: eUpdate published online September 2016 (http://www.esmo.org/Guidelines/Haematological-Malignancies). , 2016, Annals of oncology : official journal of the European Society for Medical Oncology.